Compounds > sb 225002
Page last updated: 2024-08-01 02:53:12

sb 225002

Description

1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID3854666
CHEMBL ID239767
SCHEMBL ID1110610
CHEBI ID93074
MeSH IDM0289850

Synonyms (47)

Synonym
HMS3269P11
BRD-K61323504-001-01-6
gtpl833
3-(2-bromophenyl)-1-(2-hydroxy-4-nitrophenyl)urea
HSCI1_000088
sb-225002
sb225002
sb 225002 ,
NCGC00167841-01
n-(2-hydroxy-4-nitrophenyl)-n'-(2-bromophenyl)urea
CHEMBL239767 ,
AKOS001571729
L000539
EC-000.2439
bdbm50203012
1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
n-(2-bromophenyl)-n'-(2-hydroxy-4-nitrophenyl)urea
182498-32-4
S7651
ES-0015
CS-3538
MQBZVUNNWUIPMK-UHFFFAOYSA-N
SCHEMBL1110610
AC-32729
HY-16711
B6055
HMS3648O06
DTXSID20397383
CHEBI:93074
J-011676
EX-A2754
1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea.
mfcd00954637
SY231254
HMS3677D14
Q27088712
SR-01000946394-1
sr-01000946394
BCP11852
HMS3413D14
BRD-K61323504-001-03-2
A14209
urea, n-(2-bromophenyl)-n'-(2-hydroxy-4-nitrophenyl)-
AC1209
HMS3742G17
CCG-268049
A921036

Drug Classes (1)

ClassDescription
nitrophenolAny member of the class of phenols or substituted phenols carrying at least 1 nitro group.

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.7946AID485290

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
C-X-C chemokine receptor type 1Homo sapiens (human)IC501.5110AID707880; AID707881
C-X-C chemokine receptor type 2Homo sapiens (human)IC500.0623AID1166111; AID1166121; AID1811229; AID306084; AID707879

Bioassays (23)

Assay IDTitleYearJournalArticle
AID452857Antagonist activity at CXCR2 expressed in 7w CHO cells co-expressing human recombinant APP 751 assessed as inhibition of gamma-secretase-mediated amyloid beta42 production2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
ISSN: 1464-3391		Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
AID1811216Antimigratory activity against human MDA-MB-231 cells assessed as reduction in cell migration at 2 uM measured after 24 hrs by crystal violet staining based transwell assay relative to control2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811225Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as downregulation of vimentin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811226Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as downregulation of beta-catenin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811217Anti-angiogenesis activity in HUVEC cells assessed as reduction in blood vessel area at 2 uM measured after 12 hrs by inverted microscopic analysis relative to control2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811224Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as downregulation of fibronectin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1166111Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
ISSN: 1520-4804		Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
AID1811215Antimigratory activity against human MDA-MB-231 cells assessed as reduction in cell migration at 2 uM measured after 24 hrs by wound healing assay relative to control2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1811227Down-regulation of VEGF expression in HUVEC cells assessed as 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID707880Binding affinity to CXCR12012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804		Chemokine receptor antagonists.
AID1811228Induction of ROS production in human human MDA-MB-231 cells assessed as increase in mean fluorescence intensity at 10 uM measured after 24 hrs by DCFH-DA staining based inverted microscopic analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID306084Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
ISSN: 0960-894X		Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.
AID707881Antagonist activity at CXCR1 assessed as inhibition of CXCL8 binding by cell based assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804		Chemokine receptor antagonists.
AID452859Antagonist activity at CXCR2 expressed in 7w CHO cells assessed as inhibition of GROalpha-mediated intracellular calcium mobilization by Fura-4 NW fluorescence assay2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
ISSN: 1464-3391		Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
AID1528085Antitumor activity against human SKOV3 cells xenografted in athymic Nu/Nu mouse assessed as reduction in tumor volume at 10 mg/kg/day, ip co-treated with sorafenib 30 mg/kg, po relative to sorafenib alone2020European journal of medicinal chemistry, Jan-01, Volume: 185ISSN: 1768-3254Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead.
AID1811223Inhibition of epithelial-mesenchymal transition in human MDA-MB-231 cells assessed as upregulation of E-cadherin expression at 10 uM measured after 24 hrs by Western blot assay2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID306085Selectivity for human CXCR2 over human CXCR12007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
ISSN: 0960-894X		Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.
AID707879Binding affinity to CXCR22012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
ISSN: 1520-4804		Chemokine receptor antagonists.
AID1166121Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
ISSN: 1520-4804		Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
AID1811229Antagonist activity against CXCR2 (unknown origin) by calcium flux assay2021European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346826Human CXCR2 (Chemokine receptors)1998The Journal of biological chemistry, Apr-24, Volume: 273, Issue:17
ISSN: 0021-9258		Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.

Research

Studies (92)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.09)18.2507
2000's15 (16.30)29.6817
2010's49 (53.26)24.3611
2020's27 (29.35)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other90 (97.83%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
ag 127
0
nitrophenol00low000000
2-[bis(5-methyl-2-furanyl)methyl]-6-nitrophenol
0
nitrophenol00low000000
2-[(4-chlorophenyl)methylthio]-N-(2-hydroxy-5-nitrophenyl)acetamide
0
nitrophenol00low000000
4-[[(2-methyl-5-nitro-1H-imidazol-4-yl)thio]methyl]-2-nitrophenol
0
nitrophenol00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
avapro
1
azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		2012201212.0low000010
plerixafor
1
azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant		2012201212.0low000010
tak 779
1
2012201212.0low000010
sorafenib
1
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor		202120213.0low000001
bx 471
1
2012201212.0low000010
1-(2-fluorophenyl)-3-(4-methoxy-2-nitrophenyl)urea
1
aromatic ether;
C-nitro compound		2009200915.0medium000100
aplaviroc
1
2012201212.0low000010
maraviroc
1
tropane alkaloid2012201212.0low000010
vicriviroc
1
(trifluoromethyl)benzenes2012201212.0low000010
cp 481715
1
2012201212.0medium000010
reparixin
1
monoterpenoid2012201212.0low000010
bms 193884
1
2012201212.0medium000010
sch 527123
3
201220216.3medium000021
ccx282-b
1
2012201212.0low000010
sb 656933
1
2012201212.0medium000010
cenicriviroc
1
aromatic ether;
benzazocine;
diether;
imidazoles;
secondary carboxamide;
sulfoxide		anti-HIV agent;
anti-inflammatory agent;
antirheumatic drug;
chemokine receptor 2 antagonist;
chemokine receptor 5 antagonist		2012201212.0low000010
amg 487
1
2012201212.0low000010
raltegravir
1
1,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor		2012201212.0low000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
gamma-aminobutyric acid
2
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule		2008201413.0low000110
acetic acid
1
monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent		2010201014.0low000100
2-aminoadipic acid
1
amino dicarboxylic acid;
dicarboxylic fatty acid;
non-proteinogenic alpha-amino acid		Caenorhabditis elegans metabolite;
mammalian metabolite		201820186.0low000010
formaldehyde
1
aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2010201014.0low000100
niacinamide
1
pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor		201520159.0low000010
sk&f 81297
1
benzazepine201820186.0low000010
gabapentin
1
gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic		2014201410.0low000010
indomethacin
1
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		2014201410.0low000010
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
1
chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector		2013201311.0low000010
ro 31-8220
1
imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor202120213.0low000001
vorinostat
1
dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor		2013201311.0low000010
suramin
1
naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug		2008200816.0low000100
temozolomide
1
imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug		202120213.0low000001
pilocarpine
1
pilocarpineantiglaucoma drug201720177.0low000010
quinoxalines
1
mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene		201920195.0low000010
pyrazolanthrone
1
anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector		201920195.0low000010
paraquat
1
organic cationgeroprotector;
herbicide		2014201410.0low000010
clodronic acid
1
1,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent		201820186.0low000010
8-bromo cyclic adenosine monophosphate
1
3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist		2010201014.0low000100
paclitaxel
1
taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent		201920195.0low000010
imiquimod
1
imidazoquinolineantineoplastic agent;
interferon inducer		201820186.0low000010
remifentanil
1
alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative		201620168.0low000010
triazoles
1
1,2,3-triazole202120213.0low000001
fluorocitrate
1
carbonyl compound202020204.0low000010
deoxyglucose
1
202020204.0low000010
imatinib mesylate
1
methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor		202120213.0low000001
vatalanib
1
monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist		201820186.0low000010
anacardic acid
1
hydroxy monocarboxylic acid;
hydroxybenzoic acid		anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite		2013201311.0low000010
angiotensin ii
2
amino acid zwitterion;
angiotensin II		human metabolite202020223.0low000011
sb 203580
1
imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent		201920195.0low000010
sorafenib
1
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor		201520159.0low000010
nsc 74859
1
amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor2013201311.0low000010
diprenorphine
1
morphinane alkaloid2008200816.0low000100
cocaine
1
benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		201820186.0low000010
carbenoxolone sodium
1
triterpenoid201820186.0low000010
s 1033
1
(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		202120213.0low000001
sesquiterpenes
1
2013201311.0low000010
nadp
1
202320231.0low000001
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
1
benzenes;
thiadiazolidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent		201620168.0low000010
dinoprostone
1
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		2013201311.0low000010
morphine
1
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic		2014201410.0low000010
as 605240
1
quinoxaline derivative;
thiazolidinediones		anti-inflammatory agent;
antirheumatic drug;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor		201920195.0low000010
1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol
1
2008200816.0low000100
enkephalin, leucine-2-alanine
1
2008200816.0low000100
pep005
1
202120213.0low000001
reparixin
1
monoterpenoid2008200816.0low000100
mocetinostat
4
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		2010202310.5low000211
antileukinate
1
2000200024.0medium001000
fr236924
1
202120213.0high000001
hki 272
1
nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor		202020204.0low000010
tri-n-butylstannylmethacrylate
1
2008200816.0high000100
mk 2206
1
organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201820186.0low000010
jnj-40346527
1
201720177.0medium000010
piperidines
1
201620168.0low000010
bryostatin 1
1
202120213.0low000001
interleukin-8
22
1998202311.0high0017104
minocycline
2
201820205.0low000020
wz4003
1
201720177.0medium000010
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
1
202020204.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Absence Seizure0
1
201720177.0low000010
Ache0
1
2014201410.0low000010
Acquired Immune Deficiency Syndrome0
2
2001200521.0low000200
Acquired Immunodeficiency Syndrome0
2
2001200521.0low000200
Acute Confusional Senile Dementia0
1
2009200915.0low000100
Acute Disease0
1
2008200816.0low000100
Acute Edematous Pancreatitis0
1
2013201311.0low000010
Acute Hemolytic Transfusion Reaction0
1
2011201113.0low000010
Acute Lung Injury0
1
2013201311.0low000010
Acute Lymphoid Leukemia0
1
201520159.0low000010
Acute Post-operative Pain0
1
2014201410.0low000010
Adamantiades-Behcet Disease0
1
202320231.0low000001
Adenocarcinoma Of Kidney0
1
2014201410.0low000010
Adjuvant Arthritis0
1
2010201014.0low000100
Allodynia0
6
2010201610.2low000150
Alzheimer Disease0
1
2009200915.0low000100
Anemia, Sickle Cell0
1
2011201113.0low000010
Angiogenesis, Pathologic0
7
201320217.1low000061
Animal Mammary Carcinoma0
1
202120213.0low000001
Anterior Cerebral Circulation Infarction0
1
2011201113.0low000010
Asthma0
1
201920195.0low000010
Asthma, Bronchial0
1
201920195.0low000010
Astrocytoma, Grade IV0
2
201820214.5low000011
Atrial Fibrillation0
2
202020204.0low000020
Auricular Fibrillation0
2
202020204.0low000020
Autoimmune Disease0
1
2012201212.0low000010
Autoimmune Diseases0
1
2012201212.0low000010
Behcet Syndrome0
1
202320231.0low000001
Benign Neoplasms0
1
202020204.0low000010
Benign Neoplasms, Brain0
3
201820214.3low000021
Benign Psychomotor Epilepsy, Childhood0
1
201720177.0low000010
Bile Duct Cancer0
1
2014201410.0low000010
Bile Duct Neoplasms0
1
2014201410.0low000010
Bile Duct Obstruction0
1
201920195.0low000010
Blood Poisoning0
2
201320207.5low000020
Blood Pressure, High0
1
201920195.0low000010
Body Weight0
1
2014201410.0low000010
Bone Cancer0
1
201920195.0low000010
Bone Neoplasms0
1
201920195.0low000010
Brain Diseases0
1
202320231.0low000001
Brain Disorders0
1
202320231.0low000001
Brain Edema0
2
201120208.5low000020
Brain Infarction0
1
2011201113.0low000010
Brain Inflammation0
1
201520159.0low000010
Brain Ischemia0
1
201520159.0low000010
Brain Neoplasms0
3
201820214.3low000021
Brain Swelling0
2
201120208.5low000020
Breast Cancer0
2
201920204.5low000020
Breast Neoplasms0
2
201920204.5low000020
Cancer of Esophagus0
1
202120213.0low000001
Cancer of Kidney0
1
2014201410.0low000010
Cancer of Lung0
1
2013201311.0low000010
Cancer of Mouth0
2
201220198.5low000020
Cancer of Nasopharynx0
1
2013201311.0low000010
Cancer of Ovary0
3
201320217.7low000021
Cancer of Pancreas0
1
202020204.0low000010
Cancer of Prostate0
1
201820186.0low000010
Cancer of the Thyroid0
1
201920195.0low000010
Carcinoma0
1
2013201311.0low000010
Carcinoma, Anaplastic0
1
2013201311.0low000010
Carcinoma, Epidermoid0
2
201220198.5low000020
Carcinoma, Lewis Lung0
1
2013201311.0low000010
Carcinoma, Renal Cell0
1
2014201410.0low000010
Carcinoma, Squamous Cell0
2
201220198.5low000020
Cardiac Hypertrophy0
1
201920195.0low000010
Cardiac Remodeling, Ventricular0
1
201920195.0low000010
Cardiomegaly0
1
201920195.0low000010
Cerebral Infarction, Middle Cerebral Artery0
2
2011201511.0low000020
Cerebral Ischemia0
1
201520159.0low000010
Cholangiocarcinoma0
1
2014201410.0low000010
Cholangiocellular Carcinoma0
1
2014201410.0low000010
Cholestasis0
1
201920195.0low000010
Choroid Neovascularization0
1
2009200915.0low000100
Cirrhosis0
1
202020204.0low000010
Cocaine Abuse0
1
201820186.0low000010
Cocaine-Related Disorders0
1
201820186.0low000010
Colitis0
1
2008200816.0low000100
Colitis Gravis0
1
2009200915.0low000100
Colitis, Ulcerative0
1
2009200915.0low000100
Condition, Preneoplastic0
1
202120213.0low000001
Congenital Zika Syndrome0
1
202020204.0low000010
Constriction, Pathologic0
1
201620168.0low000010
Constriction, Pathological0
1
201620168.0low000010
Cranial Nerve II Injuries0
1
202120213.0low000001
Cryptogenic Fibrosing Alveolitis0
1
201820186.0low000010
Deafness, Transitory0
1
202320231.0low000001
Diathesis0
1
202020204.0low000010
Dilatation, Pathologic0
1
202020204.0low000010
Disease Exacerbation0
3
201320188.7low000030
Disease Models, Animal0
22
200820218.1low0002182
Drug Refractory Epilepsy0
1
201720177.0low000010
Drug-Induced Cochlear Toxicity0
1
202320231.0low000001
Encephalitis0
1
201520159.0low000010
Epilepsy, Temporal Lobe0
1
201720177.0low000010
Esophageal Neoplasms0
1
202120213.0low000001
Esophageal Squamous Cell Carcinoma0
1
202120213.0low000001
Experimental Neoplasms0
1
201720177.0low000010
Extravascular Hemolysis0
1
2011201113.0low000010
Familial Nonmedullary Thyroid Cancer0
1
201920195.0low000010
Fibrosis0
1
202020204.0low000010
Gastritis, Atrophic0
1
202120213.0low000001
Glial Cell Tumors0
1
202020204.0low000010
Glioblastoma0
2
201820214.5low000011
Glioma0
1
202020204.0low000010
Granulocytic Leukemia, Chronic0
1
202120213.0low000001
HbS Disease0
1
2011201113.0low000010
Hearing Loss0
1
202320231.0low000001
Helicobacter Infections0
1
202120213.0low000001
Hemolysis0
1
2011201113.0low000010
Hemorrhage, Subarachnoid0
1
202320231.0low000001
Hepatic Infarct0
1
201920195.0low000010
Hepato-Pulmonary Syndrome0
1
201720177.0low000010
Hepatopulmonary Syndrome0
1
201720177.0low000010
Hyperlipemia0
1
201520159.0low000010
Hyperlipidemias0
1
201520159.0low000010
Hyperoxia0
1
2001200123.0low000100
Hypertension0
1
201920195.0low000010
Hypertension, Pulmonary0
1
201820186.0low000010
Hypertensive Retinopathy0
1
202220222.0low000001
Hypothermia0
1
2014201410.0low000010
Hypothermia, Accidental0
1
2014201410.0low000010
Idiopathic Pulmonary Fibrosis0
1
201820186.0low000010
Infarction, Middle Cerebral Artery0
2
2011201511.0low000020
Infections, Helicobacter0
1
202120213.0low000001
Inflammation0
7
201020209.6low000250
Injury, Ischemia-Reperfusion0
1
2008200816.0low000100
Innate Inflammatory Response0
7
201020209.6low000250
Invasiveness, Neoplasm0
4
201820204.8low000040
Kidney Neoplasms0
1
2014201410.0low000010
Leukemia, Myelogenous, Chronic, BCR-ABL Positive0
1
202120213.0low000001
Local Neoplasm Recurrence0
1
202120213.0low000001
Lung Injury, Acute0
1
2013201311.0low000010
Lung Neoplasms0
1
2013201311.0low000010
Mastitis, Bovine0
1
2007200717.0low000100
Metastase0
1
2013201311.0low000010
Mouth Neoplasms0
2
201220198.5low000020
Nasopharyngeal Neoplasms0
1
2013201311.0low000010
Necrosis0
1
201920195.0low000010
Neoplasm Metastasis0
1
2013201311.0low000010
Neoplasms0
1
202020204.0low000010
Nerve Pain0
4
201420207.0low000040
Neuralgia0
4
201420207.0low000040
Ototoxicity0
1
202320231.0low000001
Ovarian Neoplasms0
3
201320217.7low000021
Pain0
1
2014201410.0low000010
Pain, Postoperative0
1
2014201410.0low000010
Palmoplantaris Pustulosis0
1
201820186.0low000010
Pancreatic Neoplasms0
1
202020204.0low000010
Pancreatitis0
1
2013201311.0low000010
Peripheral Nerve Diseases0
1
201920195.0low000010
Peripheral Nerve Injuries0
1
2014201410.0low000010
Peripheral Nerve Injury0
1
2014201410.0low000010
Peripheral Nervous System Diseases0
1
201920195.0low000010
Pneumonia, Pneumococcal0
1
2010201014.0low000100
Precancerous Conditions0
1
202120213.0low000001
Precursor Cell Lymphoblastic Leukemia-Lymphoma0
1
201520159.0low000010
Proliferative Vitreoretinopathy0
1
202020204.0low000010
Prostatic Neoplasms0
1
201820186.0low000010
Psoriasis0
1
201820186.0low000010
Pulmonary Arterial Remodeling0
1
202020204.0low000010
Pulmonary Hypertension0
1
201820186.0low000010
Reperfusion Injury0
1
2008200816.0low000100
Seizures0
1
201720177.0low000010
Sepsis0
2
201320207.5low000020
Sepsis Associated Delirium0
1
202020204.0low000010
Subarachnoid Hemorrhage0
1
202320231.0low000001
Thyroid Neoplasms0
1
201920195.0low000010
Transfusion Reaction0
1
2011201113.0low000010
Uveitis0
1
202320231.0low000001
Vascular Diseases0
1
2011201113.0low000010
Vitreoretinopathy, Proliferative0
1
202020204.0low000010
Wounds, Penetrating0
1
2014201410.0low000010
Zika Virus Infection0
1
202020204.0low000010

Safety/Toxicity (1)

ArticleYear
Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity.
Frontiers in immunology, , Volume: 14		2023